Ignite Creation Date:
2025-12-25 @ 12:06 AM
Ignite Modification Date:
2025-12-25 @ 10:05 PM
Study NCT ID:
NCT06075758
Status:
RECRUITING
Last Update Posted:
2025-01-14
First Post:
2023-10-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000589651', 'term': 'ribociclib'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'OTHER', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 550}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-03-07', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-01', 'completionDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-01-11', 'studyFirstSubmitDate': '2023-10-04', 'studyFirstSubmitQcDate': '2023-10-04', 'lastUpdatePostDateStruct': {'date': '2025-01-14', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-10-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'AEs/SAEs/ severity and frequency', 'timeFrame': '18 months', 'description': 'Frequency/ severity of adverse events and lab abnormalities of HR+/HER2- advanced/metastatic breast cancer patients who have received Ribociclib in combination with hormonal therapy at 6and 18 months.'}], 'secondaryOutcomes': [{'measure': 'Proportion of patients who are progression-free', 'timeFrame': '6 months, 18 months', 'description': 'Percentage of progression-free patients (at 18 months following the start date of ribociclib and at the end of ribociclib treatment),'}, {'measure': 'Proportion of patients with clinical benefit response', 'timeFrame': '18 months', 'description': 'Tthe proportion of patients who have a partial or complete response or stable disease(CBR) with Ribociclib at 18 months based on Response Evaluation Criteria in Solid Tumors RECIST v1.1'}, {'measure': 'Ribociclib line of therapy treatment pattern', 'timeFrame': '18 months', 'description': 'Ribociclib line of therapy treatment pattern at 18 months'}]}, 'conditionsModule': {'keywords': ['HR+/HER2- advanced/metastatic breast cancer', 'NIS', 'Ribociclib', 'Middle eastern countries'], 'conditions': ['Breast Cancer']}, 'descriptionModule': {'briefSummary': 'This is a non-interventional, ambispective, observational cohort study describing the real-world safety data of approximately 550 Hormone receptor / Human epidermal growth factor receptor 2 (HR+/HER2-) advanced/metastatic breast cancer patients who have received ribociclib combined with hormonal therapy in pre-and postmenopausal women or men in Middle Eastern countries.', 'detailedDescription': "The investigators will have a six-month recruitment period to include the eligible subjects as per the protocol selection criteria. Retrospective patients should have been on Ribociclib in combination with hormonal therapy for at least 18 months and stopped the medication before the patient's recruitment.\n\nAmbispective patients should have initiated Ribociclib, in combination with hormonal therapy, for at least 12 months before the patient's recruitment date and are still on Ribociclib in combination with hormonal therapy at recruitment. These patients will be followed up till progression, death, Ribociclib discontinuation due to adverse events, or till a maximum period of 6 months, whichever comes first.\n\nData will be collected from patient electronic medical records in the sites chosen for patients who received Ribociclib, in combination with hormonal therapy, in the first or second-line setting available in the relevant institutions.\n\nA total of 550 patients is planned for this study. The planned sample size should capture very common adverse events reported in previous studies as well as adverse events ≥ 10% occurring in grade 3 and grade 4 with precision ±2.5%."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '100 Years', 'minimumAge': '18 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'HR+/HER2- advanced/metastatic breast cancer patients who have received Ribociclib in combination with hormonal therapy in pre-and postmenopausal women or men in Middle Eastern countries', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Adult patients ≥ 18 years old at the time of receiving Ribociclib in combination with hormonal therapy.\n2. Advanced /metastatic breast cancer\n3. Estrogen-receptor-positive and/or progesterone receptor-positive breast cancer.\n4. HER2-negative breast cancer.\n5. Patients who received or currently receiving Ribociclib in combination with hormonal therapy in the first or second-line settings as per the routine practice.\n6. For the ambispective part, patients should have initiated the Ribociclib, in combination with hormonal therapy, line of treatment at least 12 months before the patient's recruitment date and still continuingcontinuing the drug at the baseline visit.\n7. For retrospective patients only, the patients should have been on Ribocilib, in combination with hormonal therapy, for at least 18 months and stopped Ribociclib before the SIV date.enrollment\n8. For ambispective part, patients agree to sign informed consent before their enrollment.\n\nExclusion Criteria:\n\n1. Ribociclib-based treatment regimen beyond the second line.\n2. Patients are currently participating in any other clinical trials.\n3. Patient with a known hypersensitivity to any of the excipients of Ribociclib.\n4. Patients who previously received any other CDK4/6 inhibitor .\n5. For ambispective patients, patients who refuse to sign the informed consent"}, 'identificationModule': {'nctId': 'NCT06075758', 'briefTitle': 'A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer', 'organization': {'class': 'INDUSTRY', 'fullName': 'Novartis'}, 'officialTitle': 'Real-World Evidence Study for the Safety and Effectiveness of Ribociclib in Combination With Hormonal Therapy in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer in the Middle East Region', 'orgStudyIdInfo': {'id': 'CLEE011AIC01'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'ribociclib ambispective', 'description': "Ambispective patients should have initiated Ribociclib, in combination with hormonal therapy, for at least 12 months before the patient's recruitment date and are still on Ribociclib in combination with hormonal therapy at recruitment. These patients will be followed up till progression, death, Ribociclib discontinuation due to adverse events, or till a maximum period of 6 months, whichever comes first.", 'interventionNames': ['Other: ribociclib']}, {'label': 'ribociclib retrospective', 'description': "Retrospective patients should have been on Ribociclib in combination with hormonal therapy for at least 18 months and stopped the medication before the patient's recruitment", 'interventionNames': ['Other: ribociclib']}], 'interventions': [{'name': 'ribociclib', 'type': 'OTHER', 'otherNames': ['CLEE011'], 'description': 'There is no treatment allocation for NIS trials, patients on administered ribociclib by prescription will be enrolled.\n\nTreatment plan represents the prescription.', 'armGroupLabels': ['ribociclib ambispective', 'ribociclib retrospective']}]}, 'contactsLocationsModule': {'locations': [{'zip': '11941', 'city': 'Amman', 'status': 'RECRUITING', 'country': 'Jordan', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 31.95522, 'lon': 35.94503}}, {'zip': '1331', 'city': 'Muscat', 'status': 'RECRUITING', 'country': 'Oman', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 23.58413, 'lon': 58.40778}}, {'zip': '11211', 'city': 'Riyadh', 'status': 'RECRUITING', 'country': 'Saudi Arabia', 'facility': 'Novartis Investigative Site', 'geoPoint': {'lat': 24.68773, 'lon': 46.72185}}, {'city': 'Al Ain Abu Dhabi', 'state': 'United Arab Emirates', 'status': 'RECRUITING', 'country': 'United Arab Emirates', 'facility': 'Novartis Investigative Site'}], 'centralContacts': [{'name': 'Novartis Pharmaceuticals', 'role': 'CONTACT', 'email': 'novartis.email@novartis.com', 'phone': '+41613241111'}, {'name': 'Novartis Pharmaceuticals', 'role': 'CONTACT'}], 'overallOfficials': [{'name': 'Novartis Pharmaceuticals', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Novartis Pharmaceuticals'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Novartis Pharmaceuticals', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}